NGL Fine-Chem Limited — Results, 10-07-2025: Reply to Clarification- Financial results

NGL Fine-Chem Limited has announced a board meeting on August 12, 2025, to consider the financial results for the quarter and half-year.

For the financial year ended March 31, 2025, the Board approved the audited standalone and consolidated financial results. Key highlights include:

- Consolidated revenue from operations stood at ₹368.26 Cr, up from ₹293.87 Cr in the previous year.

- Standalone revenue from operations was ₹359.20 Cr, compared to ₹328.97 Cr last year.

- Consolidated profit before tax was ₹27.71 Cr, up from ₹20.88 Cr.

- Standalone profit before tax increased to ₹28.82 Cr from ₹20.51 Cr.

- Consolidated net profit after tax was ₹21.12 Cr, compared to ₹41.32 Cr in the previous year, impacted by tax adjustments.

- Standalone net profit after tax was ₹11.32 Cr, down from ₹38.52 Cr.

- Earnings per share (EPS) on a consolidated basis stood at ₹6.83 (basic), compared to ₹13.36 last year.

- The Board has approved a final dividend of ₹1.75 per equity share of ₹5 each, aggregating to ₹10.81 Cr.

The company’s asset base remains strong with consolidated total assets of ₹839.13 Cr and standalone assets of ₹427.62 Cr. Net cash from operating activities was ₹35.52 Cr for the year.

Key management changes include the appointment of Mr. Sudhir Deo as an Independent Director for five years and Mr. Rahul Nachane as Managing Director for five years starting June 1, 2025.

The audit reports for both standalone and consolidated results were unmodified, confirming clean financials. The company continues to focus on its pharmaceutical segment with diversified geographical revenue streams including India, Europe, Asia Pacific, and the US.